HIGHLIGHTS
- who: Stephen C. Frederico et al. from the Jilin University, China have published the article: Neoadjuvant immune checkpoint inhibition in the management of glioblastoma: Exploring a new frontier, in the Journal: (JOURNAL)
- what: To evaluating whether this approach provided an OS and/or PFS benefit, the authors will also discuss the specific ways this approach enhanced immunological response. The primary endpoint for this study was the proportion of patients with complete response, partial response, or stable disease after 12 weeks which was assessed using modified WHO criteria . Findings from this study demonstrated that in patients . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.